Evidence map›Paper›PMID 29312137›Full record

ArticleFrontiers in neurology2017

Elevated Serum α-Synuclein Autoantibodies in Patients with Parkinson's Disease Relative to Alzheimer's Disease and Controls.

Ali Shalash, Mohamed Salama, Marianne Makar, Tamer Roushdy, Hanan Hany Elrassas, Wael Mohamed, Mahmoud El-Balkimy, Mohamed Abou Donia

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04062279 (Predictors of Parkinson's Disease Progression in Sample of Egyptian Patients; Clinical and Biochemical), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04062279 unknown statusnot on this mapstarted 2019, after this paper: background citation

Predictors of Parkinson's Disease Progression in Sample of Egyptian Patients; Clinical and Biochemical

Typeobservational_patient_registrySponsorAin Shams UniversityRan2019 to 2024Enrolled100ConditionsParkinson Disease, Cognitive Dysfunction, BiomarkersArmsserum alpha synuclein autoantibodies, motor and non motor scales
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. T cells, α-synuclein and Parkinson disease.Handbook of clinical neurology · 2022
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Ali ShalashDepartment of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed SalamaMedical Experimental Research Centre (MERC), Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Marianne MakarDepartment of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Tamer RoushdyDepartment of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Hanan Hany ElrassasFaculty of Medicine, Okasha Institute of Psychiatry, Ain Shams University, Cairo, Egypt.
Wael MohamedFaculty of Medicine, Department of Clinical Pharmacology, Menoufia University, Shebin El-Kom, Egypt.
Mahmoud El-BalkimyDepartment of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed Abou DoniaDepartment of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, United States.
Ain Shams University · EGDuke Medical Center · USInternational Islamic University Malaysia · MYMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis of neurodegenerative diseases is of paramount importance for successful treatment. Lack of sensitive and early biomarkers for diagnosis of diseases like Parkinson's disease (PD) is a handicapping problem for all movement disorders specialists. Using serum autoimmune antibodies (AIAs) against neural proteins is a new promising strategy to diagnose brain disorders through non-invasive and cost-effective method. In the present study, we measured the level of AIAs against α-synuclein (α-syn), which is an important protein involved in the pathogenesis of PD. In our study patients with PD (46 patients), Alzheimer's disease (AD) (27 patients) and healthy controls (20 patients) were evaluated according to their sera α-syn AIAs levels. Interestingly, α-syn AIAs were significantly elevated in PD group compared to AD and healthy controls, which advocates their use for diagnosis of PD.

Indexed as

Alzheimer’s diseaseautoantibodiesbiomarkersParkinson’s diseaseα synuclein

Identifiers

PMID29312137
PMCPMC5744443
OpenAlexW2775920839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.